NCT02447003View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

PHASE2CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

June 11, 2015

Primary Completion Date

February 18, 2019

Study Completion Date

January 31, 2020

Conditions
Breast Cancer
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion of 200 mg.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02447003 - Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | Biotech Hunter | Biotech Hunter